

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 683 785 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
26.07.2006 Bulletin 2006/30

(21) Application number: **04818213.3**

(22) Date of filing: **08.11.2004**

(51) Int Cl.:
C07C 275/34 ^(2006.01) **C07C 271/58** ^(2006.01)
C07C 273/18 ^(2006.01) **C07D 215/48** ^(2006.01)

(86) International application number:
PCT/JP2004/016526

(87) International publication number:
WO 2005/044788 (19.05.2005 Gazette 2005/20)

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR**
Designated Extension States:
AL HR LT LV MK YU

(30) Priority: **11.11.2003 JP 2003381249**


(71) Applicant: **Eisai Co., Ltd.**
Tokyo 112-8088 (JP)

(72) Inventors:
• **NAITO, Toshihiko,**
Eisai Co., Ltd. Tsukuba Site
Tsukuba-shi,
Ibaraki 300-2635 (JP)
• **YOSHIZAWA, Kazuhiro,**
Eisai Co., Ltd. Kashima Site
Kashima-gun,
Ibaraki 314-0255 (JP)


(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **UREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME**


(57) A process for preparing a compound (C) represented by the following formula:



wherein R¹ represents hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl, and R² represents hydrogen or methoxy,
characterized by reacting a compound (A-1) represented by the following formula:



wherein R¹ has the same definition as above,
with a compound (B) represented by the following formula:



wherein R² has the same definition as above, and L represents a leaving group, is provided. Compound (C) is effective for prevention or treatment of various diseases associated with angiogenesis neoplasia.

EP 1 683 785 A1

Description


Technical Field

5 [0001] The present invention relates to urea derivatives which are effective for prevention or treatment of various diseases associated with abnormal angiogenesis, and to processes for preparing the same.

Background Art

10 [0002] Urea derivatives represented by the general formula (C):

[Chemical Formula 1]



25 wherein R¹ represents hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl, and R² represents hydrogen or methoxy, are known to exhibit excellent angiogenesis-inhibitory action (Patent document 1). Urea derivatives represented by general formula (C) also are known to exhibit powerful c-Kit kinase inhibitory action (Patent document 2, Non-patent document 1).

30 [0003] The preparing process described in Patent document 1 is useful as a process for preparing urea derivatives, but much room still remains for improvement in terms of total yield. It has therefore been desirable to develop an industrial process for preparing urea derivatives that gives a good total yield, as well as useful intermediates for such a preparing process.

[0004] Patent document 1 never discloses an efficient process for preparing urea compounds represented by the general formula (C), nor the useful intermediates represented by the general formulas (A-1) and (A-2), as according to the present invention.

35 [0005] Patent document 1: WO02/32872

[0006] Patent document 2: WO2004/080462

[0007] Non-patent document 1: 95th Annual Meeting Proceedings, AACR (American Association for Cancer Research), Volume 45, Page 1070-1071, 2004.

40 Disclosure of the Invention

[0008] It is an object of the present invention to provide novel production intermediates of urea derivatives which are effective for prevention or treatment of various diseases associated with abnormal angiogenesis, as well as processes for their production.

45 [0009] As a result of much avid research in light of the circumstances described above, the present inventors discovered novel production intermediates of urea derivatives which are effective for prevention or treatment of various diseases associated with abnormal angiogenesis, as well as processes for their production, and have thereupon completed this invention. Specifically, the invention provides the following:

50 [1] A compound (A-1) or a salt thereof or a hydrate of the foregoing represented by the following formula:

[Chemical Formula 2]




wherein R¹ represents hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl.

[2] A compound or a salt thereof or a hydrate of the foregoing according to [1] wherein R¹ is hydrogen, methyl, ethyl, n-propyl or cyclopropyl;


[3] A compound or a salt thereof or a hydrate of the foregoing according to [1] wherein R¹ is cyclopropyl;

[4] A process for preparing a compound (A-1) represented by the following formula:


[Chemical Formula 6]




wherein R¹ has the same definition as above, characterized by reacting a compound (A-3) represented by the following formula:



wherein Ar represents C₆₋₁₀ aryl optionally having 1 or 2 substituents selected from the group consisting of halogen, methyl, methoxy and nitro, with a compound (A-4) represented by the following formula:



to afford a compound (A-2) represented by the following formula:



wherein Ar has the same definition as above, and then reacting the compound (A-2) with a compound represented by the formula R¹-NH₂, wherein R¹ has the same definition as above;


[5] A process according to [4], wherein R¹ is hydrogen, methyl, ethyl, n-propyl or cyclopropyl;

[6] A process according to [4], wherein R¹ is cyclopropyl;

[7] A process according to any one of [4] to [6], wherein Ar is phenyl;

[8] A compound (A-2) or a salt thereof or a hydrate of the foregoing represented by the following formula:

[Chemical Formula 7]




wherein Ar has the same definition as above;

[9] A compound or a salt thereof or a hydrate of the foregoing according to [8], wherein Ar is phenyl;


[10] A process for preparing compound (C) or a salt thereof represented by the following formula:

[Chemical Formula 10]




wherein R¹ and R² have the same definitions as above, characterized by reacting a compound (A-1) represented by the following formula:

[Chemical Formula 8]



wherein R¹ has the same definition as above, with a compound (B) represented by the following formula:

[Chemical Formula 9]



wherein R² represents hydrogen or methoxy, and L represents a leaving group;

[11] A process according to [10], characterized by using a base;

[12] A process according to [11], wherein the base is an alkali metal carbonate or an alkali metal alkoxide;

- [13] A process according to [11], wherein the base is cesium carbonate, potassium carbonate or potassium t-butoxide;
 [14] A process according to any one of [10] to [13], wherein R¹ is hydrogen, methyl, ethyl, n-propyl or cyclopropyl;
 [15] A process according to any one of [10] to [13], wherein R¹ is cyclopropyl;
 [16] A process according to any one of [10] to [15], wherein R² is hydrogen;
 [17] A process according to any one of [10] to [16], wherein L is chlorine.

Best Mode for Carrying Out the Invention

[0010] The present invention will now be explained in detail, including explanations of the meanings of the terms and symbols used throughout the present specification.

[0011] The compounds or salts of the invention may be anhydrides, hydrates or solvates.

[0012] The term "C₁₋₆ alkyl" as used throughout the present specification refers to a monovalent group derived by removing any hydrogen atom from a C1-6 aliphatic hydrocarbon. It is a C1-6 straight- or branched-chain alkyl group, and as specific examples there may be mentioned methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl, among which methyl, ethyl and n-propyl are preferred.

[0013] The term "C₃₋₈ cycloalkyl" as used throughout the present specification refers to a C3-8 cyclic aliphatic hydrocarbon group, and as specific examples there may be mentioned cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, among which cyclopropyl is preferred.

[0014] The term "C₆₋₁₀ aryl" as used throughout the present specification refers to a C6-10 aromatic hydrocarbon ring group, and as specific examples there may be mentioned phenyl, 1-naphthyl and 2-naphthyl, among which phenyl is preferred.

[0015] The term "halogen" as used throughout the present specification refers to fluorine, chlorine, bromine or iodine, among which chlorine is preferred.

[0016] The term "base" as used throughout the present specification refers to an organic base (for example, pyridine, 2,6-lutidine, collidine, triethylamine, diisopropylethylamine, diazabicyclo[5.4.0]undec-7-ene, etc.) or an inorganic base (an alkali metal carbonate (for example, cesium carbonate, potassium carbonate, sodium carbonate, etc.), an alkali metal alkoxide (for example, potassium t-butoxide, sodium ethoxide, etc.), an alkali metal hydride (for example, potassium hydride, sodium hydride, etc.), or an alkali metal hydroxide (for example, potassium hydroxide, sodium hydroxide, etc.). The base used in the step of reacting a compound (A-1) with a compound (B) to afford compound (C) is preferably an alkali metal carbonate or an alkali metal alkoxide, and more preferably cesium carbonate, potassium carbonate or potassium t-butoxide.

[0017] As examples of "salts" referred to throughout the present specification there may be mentioned inorganic acid salts, organic acid salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts.

[0018] As preferred examples of inorganic acid salts there may be mentioned salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, and as preferred examples of organic acid salts there may be mentioned salts with acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid and p-toluenesulfonic acid.

[0019] As preferred examples of inorganic base salts there may be mentioned alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium salts and magnesium salts, and aluminum salts or ammonium salts. As preferred examples of organic base salts there may be mentioned salts with diethylamine, diethanolamine, meglumine and N,N-dibenzylethylenediamine.

[0020] As preferred examples of acidic amino acid salts there may be mentioned salts with aspartic acid and glutamic acid, and as preferred examples of basic amino acid salts there may be mentioned salts with arginine, lysine and ornithine.


[0021] The term "leaving group" as used throughout the present specification may be any group which is usually known as a leaving group in organic synthesis, without any particular restrictions, and as specific examples there may be mentioned halogens such as chlorine, bromine and iodine, alkylsulfonyloxy groups such as methanesulfonyloxy, trifluoromethanesulfonyloxy and ethanesulfonyloxy, arylsulfonyloxy groups such as benzenesulfonyloxy and p-toluenesulfonyloxy, alkoxy groups such as methoxy and ethoxy, and alkylthio groups such as methylthio and ethylthio. Preferred "leaving groups" are halogens such as chlorine, bromine and iodine, with chlorine being especially preferred.

[0022] Preparing processes according to the invention will now be explained in detail.

Preparing Process 1, Process for preparing urea (A-1)

[0023]

[Chemical Formula 11]



wherein the symbols have the same definitions as above.

[Step 1-1]

15 [0024] This is a step of reacting a carbamating reagent (A-3) such as phenyl chloroformate with a compound (A-4) to afford a compound (A-2). The reaction solvent used may be dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, ethyl acetate or the like. The reaction may also utilize a base such as pyridine. The carbamating reagent (A-3) is used at 1-2 equivalents with respect to the compound (A-4). The base is used at 1-4 equivalents with respect to the compound (A-4). The reaction time is from 10 minutes to 30 hours. The reaction temperature is from 0°C to heated reflux temperature, and is preferably between 0°C and room temperature.


[Step 1-2]

25 [0025] This is a step of reacting an amine derivative R¹-NH₂ with the compound (A-2) to afford a compound (A-1). The reaction solvent used may be dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, ethyl acetate, acetonitrile, toluene, chloroform or the like. The reaction may also utilize an organic base (for example, pyridine, triethylamine, diisopropylethylamine, etc.) or inorganic base (an alkali metal carbonate (for example, cesium carbonate, potassium carbonate, sodium carbonate, etc.) or an alkali metal hydride (for example, potassium hydride, sodium hydride, etc.)). The amine derivative is used at 1-3 equivalents with respect to the compound (A-2). The base is used at 1-3 equivalents with respect to the compound (A-2). The reaction time is from 10 minutes to 30 hours. The reaction temperature is from 0°C to heated reflux temperature, and is preferably between 0°C and room temperature.

35 Preparing Process 2, Process for preparing compound (C)

[0026]

[Chemical Formula 12]



wherein the symbols have the same definitions as above.

[Step 2]

55 [0027] This is a step of reacting a compound (A-1) with a compound (B) to afford a compound (C). The reaction solvent used may be 1-methylpyrrolidone, dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-

imidazolidinone, toluene, chlorobenzene or the like. As appropriate bases there may be added an organic base (for example, pyridine, 2,6-lutidine, collidine, triethylamine, diisopropylethylamine, diazabicyclo[5.4.0]undec-7-ene, etc.) or an inorganic base (an alkali metal carbonate (for example, cesium carbonate, potassium carbonate, sodium carbonate, etc.), an alkali metal alkoxide (for example, potassium t-butoxide, sodium ethoxide, etc.), an alkali metal hydride (for example, potassium hydride, sodium hydride, etc.), or an alkali metal hydroxide (for example, potassium hydroxide, sodium hydroxide, etc.)). As such bases there are preferred alkali metal carbonates and alkali metal alkoxides, among which cesium carbonate, potassium carbonate and potassium t-butoxide are especially preferred. The compound (A-1) is used at 1-2 equivalents with respect to the compound (B). The base is used at 1-2 equivalents with respect to the compound (B). The reaction time is from 10 minutes to 48 hours. The reaction temperature is from room temperature to heated reflux temperature, and is preferably between 40°C and 80°C.

[0028] Upon completion of the reaction, purification may be performed if necessary by an ordinary treatment method, for example, column chromatography using silica gel or an adsorption resin, or by recrystallization from an appropriate solvent.


Examples

[0029] Examples will now be described to facilitate understanding of the invention, but the invention is not limited to these examples.

(Example 1) phenyl N-(2-chloro-4-hydroxyphenyl)carbamate

[0030]

[Chemical Formula 13]




[0031] After suspending 4-amino-3-chlorophenol (23.7 g) in N,N-dimethylformamide (100 mL) and adding pyridine (23.4 mL) while cooling on ice, phenyl chloroformate (23.2 mL) was added dropwise below 20°C. Stirring was performed at room temperature for 30 minutes, and then water (400 mL), ethyl acetate (300 mL) and 6N HCl (48 mL) were added, the mixture was stirred and the organic layer was separated. The organic layer was washed twice with 10% brine (200 mL), and dried over magnesium sulfate. The solvent was removed to give 46 g of the title compound as a solid.

¹H-NMR(CDCl₃): 5.12(1H, br s), 6.75(1H, dd, J=9.2, 2.8Hz), 6.92(1H, d, J=2.8Hz), 7.18-7.28(4H, m), 7.37-7.43(2H, m), 7.94(1H, br s)

(Example 2) 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea

[0032]

[Chemical Formula 14]



[0033] After dissolving phenyl N-(2-chloro-4-hydroxyphenyl)carbamate in N,N-dimethylformamide (100 mL), cyclopropylamine (22.7 mL) was added while cooling on ice and the mixture was stirred overnight at room temperature. Water


(400 mL), ethyl acetate (300 mL) and 6N HCl (55 mL) were then added, the mixture was stirred and the organic layer was separated. The organic layer was washed twice with 10% brine (200 mL), and dried over magnesium sulfate. Prism crystals obtained by concentrating the solvent were filtered and washed with heptane to give 22.8 g of the title compound (77% yield from 4-amino-3-chlorophenol).

¹H-NMR(CDCl₃): 0.72-0.77(2H, m), 0.87-0.95(2H, m), 2.60-2.65(1H, m), 4.89(1H, br s), 5.60(1H, br s), 6.71(1H, dd, J=8.8, 2.8Hz), 6.88(1H, d, J=2.8Hz), 7.24-7.30(1H, br s), 7.90(1H, d, J=8.8H)

(Example 3) 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0034]

[Chemical Formula 15]



[0035] To dimethylsulfoxide (20 mL) were added 7-methoxy-4-chloro-quinoline-6-carboxamide (0.983 g), 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (1.13 g) and cesium carbonate (2.71 g), followed by heating and stirring at 70 °C for 23 hours. After the reaction mixture was allowed to cool down to room temperature, water (50 mL) was added, and the produced crystals were collected by filtration to give 1.56 g of the title compound (88% yield).

[0036] ¹H-NMR(d₆-DMSO): 0.41(2H, m), 0.66(2H, m), 2.56(1H, m), 4.01(3H, s), 6.51(1H, d, J=5.6Hz), 7.18(1H, d, J=2.8Hz), 7.23(1H, dd, J=2.8, 8.8Hz), 7.48(1H, d, J=2.8Hz), 7.50(1H, s), 7.72(1H, s), 7.84(1H, s), 7.97(1H, s), 8.25(1H, d, J=8.8Hz), 8.64(1H, s), 8.65(1H, d, J=5.6Hz)

(Example 4) 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0037] In a reaction vessel were placed 7-methoxy-4-chloro-quinoline-6-carboxamide (5.00 kg, 21.13 mol), dimethylsulfoxide (55.05 kg), 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (5.75 kg, 25.35 mol) and potassium t-butoxide (2.85 kg, 25.35 mol) in that order, under a nitrogen atmosphere. After stirring at 20 °C for 30 minutes, the temperature was raised to 65 °C over a period of 2.5 hours. After stirring at the same temperature for 19 hours, 33% (v/v) acetone water (5.0 L) and water (10.0 L) were added dropwise over a period of 3.5 hours. Upon completion of the dropwise addition, the mixture was stirred at 60 °C for 2 hours, and 33% (v/v) acetone water (20.0 L) and water (40.0 L) were added dropwise at 55 °C or higher over a period of 1 hour. After then stirring at 40 °C for 16 hours, the precipitated crystals were collected by filtration using a nitrogen pressure filter, and the crystals were washed with 33% (v/v) acetone water (33.3 L), water (66.7 L) and acetone (50.0 L) in that order. The obtained crystals were dried at 60 °C for 22 hours using a conical vacuum drier to give 7.78 kg of the title compound (96.3% yield).

[0038] The processes for preparing urea derivatives according to the invention allow efficient production of urea derivatives, which are effective for prevention or treatment of various diseases associated with abnormal angiogenesis, by industrial preparing processes. The urea derivative intermediates according to the invention are useful as intermediates for efficient production of the aforementioned urea derivatives.


Industrial Applicability

[0039] The processes for preparing urea derivatives according to the invention allow efficient production of urea derivatives, which are effective for prevention or treatment of various diseases associated with abnormal angiogenesis, by industrial preparing processes. The urea derivative intermediates according to the invention are useful as intermediates for efficient production of the aforementioned urea derivatives.

Claims

1. A compound (A-1) or a salt thereof or a hydrate of the foregoing represented by the following formula:


[Chemical Formula 1]



wherein R¹ represents hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl.


2. A compound or a salt thereof or a hydrate of the foregoing according to claim 1, wherein R¹ is hydrogen, methyl, ethyl, n-propyl or cyclopropyl.
3. A compound or a salt thereof or a hydrate of the foregoing according to claim 1, wherein R¹ is cyclopropyl.
4. A process for preparing a compound (A-1) represented by the following formula:

[Chemical Formula 5]




wherein R¹ has the same definition as above, **characterized by** reacting a compound (A-3) represented by the following formula:

[Chemical Formula 2]




wherein Ar represents C₆₋₁₀ aryl optionally having 1 or 2 substituents selected from the group consisting of halogen, methyl, methoxy and nitro, with a compound (A-4) represented by the following formula:

[Chemical Formula 3]



to afford a compound (A-2) represented by the following formula:


[Chemical Formula 4]



wherein Ar has the same definition as above, and then reacting the compound (A-2) with a compound represented by the formula R^1-NH_2 , wherein R^1 has the same definition as above.

5. A process according to claim 4, wherein R^1 is hydrogen, methyl, ethyl, n-propyl or cyclopropyl.
6. A process according to claim 4, wherein R^1 is cyclopropyl.
7. A process according to any one of claims 4 to 6, wherein Ar is phenyl.
8. A compound (A-2) or a salt thereof or a hydrate of the foregoing represented by the following formula:


[Chemical Formula 6]



wherein Ar has the same definition as above.


9. A compound or a salt thereof or a hydrate of the foregoing according to claim 8, wherein Ar is phenyl.
10. A process for preparing a compound (C) or a salt thereof represented by the following formula:

[Chemical Formula 9]




wherein R^1 and R^2 have the same definitions as above, **characterized by** reacting a compound (A-1) represented by the following formula:

[Chemical Formula 7]



wherein R^1 has the same definition as above, with a compound (B) represented by the following formula:

[Chemical Formula 8]



10 wherein-R² represents hydrogen or methoxy, and L represents a leaving group.

11. A process according to claim 10, **characterized by** using a base.

15 12. A process according to claim 11, wherein the base is an alkali metal carbonate or an alkali metal alkoxide.

13. A process according to claim 11, wherein the base is cesium carbonate, potassium carbonate or potassium t-butoxide.

20 14. A process according to any one of claims 10 to 13, wherein R¹ is hydrogen, methyl, ethyl, n-propyl or cyclopropyl.

15. A process according to any one of claims 10 to 13, wherein R¹ is cyclopropyl.

16. A process according to any one of claims 10 to 15, wherein R² is hydrogen.

25 17. A process according to any one of claims 10 to 16, wherein L is chlorine.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/016526

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C07C275/34, 271/58, 273/18, C07D215/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C07C275/34, 271/58, 273/18, C07D215/48

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA (STN), REGISTRY (STN), CASREACT (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2002/32872 A1 (Eisai Co., Ltd.), 25 April, 2002 (25.04.02), Claims; (particularly, Claim 11), production method 2-2, (page 53), preparation example 4, (page 116), examples 368, 417, 619, 620, (pages 374, 400, 539, 540) & US 2004/53908 A1 & EP 1415987 A1	1-17
Y	GARDNER, G. et al., 'In Vitro Activity of Sorghum-Selective Fluorophenyl Urea Herbicides', Pesticide Biochemistry and Physiology, 1985, Vol.24, No.3, pages 285 to 297	1-17

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

01 February, 2005 (01.02.05)

Date of mailing of the international search report

22 February, 2005 (22.02.05)

Name and mailing address of the ISA/

Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/016526

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NUGIEL, D.A., et al., 'Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors., 2.Probing the Indeno Ring Substituent Pattern', Journal of Medicinal Chemistry, 2002, Vol.45, No.24, pages 5224 to 5232	1-17
E,X	WO 2004/101526 A1 (Eisai Co., Ltd.), 25 November, 2004 (25.11.04), Par. Nos. [0028] to [0034], [0049] to [0051] (Family: none)	1-17
A	WO 2004/080462 A1 (Eisai Co., Ltd.), 23 September, 2004 (23.09.04), & US 2004/253205 A1	1-17
A	WO 2004/080966 A1 (Ono Pharmaceutical Co., Ltd.), 23 September, 2004 (23.09.04), (Family: none)	1-17

Form PCT/ISA/210 (continuation of second sheet) (January 2004)